Idiopathic Gastroparesis Registry Using a Predominant-Symptom Classification
NCT ID: NCT01173484
Last Updated: 2017-04-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
15 participants
OBSERVATIONAL
2010-06-30
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
NCT04661215
Gastroparesis Registry 3
NCT03680859
Nutritional Drink in Gastroparesis
NCT03500354
Gastroparesis Registry 2
NCT01696747
Gastroparesis Registry 4
NCT05846802
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We believe our clinical classification for gastroparesis is a clinical useful tool in the management of patients with idiopathic gastroparesis to predict clinical severity, treatment response, and future prognosis. Patients with vomiting-predominant gastroparesis will be more likely to have an underlying cause, such as viral infection or impaired glucose tolerance with vagal neuropathy. Their symptoms will likely be persistent. Patients with dyspepsia-predominant gastroparesis mimic those with functional dyspepsia and are unlikely to have complications such as weight loss, and dehydration. The necessity of enteric feeding in these patients is also unlikely. Prokinetics may help since delayed gastric emptying may contribute to epigastric pain or postprandial distress. Finding and treating small intestinal bacterial overgrowth as well as suggesting lifestyle and dietary modifications may be helpful. Patients with regurgitation-predominant gastroparesis may benefit most by improving their delayed gastric emptying. Their gastroparesis may cause reflux-like symptoms, especially at night.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vomiting-predominant idiopathic gastroparesis
Vomiting with retching and nausea are the most bothersome symptoms
No interventions assigned to this group
Dyspepsia-predominant idiopathic gastroparesis
Unpleasant or troublesome sensation (discomfort or pain) centered in the upper abdomen is the most bothersome symptom; this sensation may be characterized by or associated with upper abdominal fullness, fullness after small meals, bloating, or nausea
No interventions assigned to this group
Regurgitation-predominant idiopathic gastroparesis
Effortless regurgitation of acid or undigested food or heartburn is the most bothersome symptom
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Abnormal 4-hour gastric emptying scan within the past 3 months.
* Initial investigation, based on the AGA Technical Review for gastroparesis, is non-diagnostic for an underlying cause
Exclusion Criteria
* Presence of post-surgical gastroparesis: gastric surgery with vagotomy (with or without gastric resection, esophagectomy; surgery without vagotomy (fundoplication, bariatric surgery, heart-lung transplant).
* Presence of neuromuscular diseases: multiple sclerosis, chronic idiopathic demyelinating polyneuropathy, myotonic dystrophy.
* Presence of connective tissue diseases: systemic sclerosis, mixed connective tissue disorder, polymyositis, dermatomyositis, lupus.
* Presence of autonomic diseases: Central (Parkinson, multiple system atrophy, Lewy body disease, brainstem disease) or Peripheral (idiopathic dysautonomia, amyloidosis, immune-mediated disease, vitamin B12 deficiency, mitochondrial disorder, porphyria, hereditary sensory autonomic neuropathy).
* Presence of paraneoplastic syndrome: small cell lung cancer, multiple myeloma, breast cancer, lymphomas, pancreatic cancer.
* Taking dopamine agonists on a daily basis.
* Presence of known viral infection (Epstein-Barr, cytomegalovirus, herpes simplex, rotavirus), Chagas disease.
* Presence of gastric outlet, small bowel or colon mechanical obstruction.
* Presence of gastric electrical stimulator.
* Non-ambulatory patients: bed-ridden, nursing home resident, etc.
* Presence of active cancer or undergoing cancer treatment.
* Less than 16 years old.
* Pregnancy.
* Unable to provide informed consent.
* Prisoners.
16 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Louisville
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John M. Wo, MD
Role: PRINCIPAL_INVESTIGATOR
University of Louisville School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Louisville
Louisville, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-0569
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.